Menu
Live News EQUITY H impact

Gilead: FDA OKs Trodelvy

The FDA has approved Gilead's Trodelvy for two indications, one for monotherapy and the other for combination with pembrolizumab.

GILD

- First Indication For Monotherapy, Second For Combination With Pembrolizumab - Oks Gilead s Trodelvy For Two Indications